SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

Click Holdings ($CLIK) is trending due to significant revenue growth and its micro-float status, drawing attention from traders seeking potential for substantial gains. Community members highlight the stock's small float and revenue increase, anticipating a potential breakout. Some are attributing the recent price action to a bot alert and solid news, while also comparing it to other low-float runners.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is trending due to community discussion around an Adweek article and its potential impact from Amazon's competitive moves in the DSP space, with many suggesting the article was misleading and reporting it to the SEC. Community members are debating the long-term value of TTD amidst competition from larger tech companies and potential market manipulation. Despite concerns, some bulls remain confident in the stock's potential, citing strong fundamentals and potential for a rebound.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

NEGG is trending as retail traders discuss a potential short squeeze, with community members pointing to high borrowing costs for short sellers and a limited float. Talk centers around a large buy order that could trigger significant upward movement. Some traders are comfortable holding shares while others are looking for an entry point or taking profits.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending due to an upcoming FDA decision on their drug Revuforj for a specific type of leukemia, with the community actively discussing the potential market impact and likelihood of approval. While some express concerns about potential side effects and a history of sell-offs post-approval, others point to the drug's efficacy and the company's strong financial position, anticipating a significant upside if approved. Community members are closely monitoring discussions around analyst price targets, short interest, and potential buyout scenarios.

Picard Medical, Inc. is a medical technology company, which manufactures and sells the only U.S. FDA, and Health Canada approved implantable SynCardia TAH. It develops the first fully implantable SynCardia TAH as an alternative to heart transplantation for patients with biventricular heart failure in the U.S. and around the world. The company is headquartered in Tucson, AZ.

Picard Medical Inc.

PMI is trending due to after-hours price action and community speculation about a potential short squeeze or upcoming news, despite the company stating they are unaware of any material changes. Traders are actively discussing potential price movements and the possibility of dilution, creating volatility. The stock's movement is also attracting attention as a potential play in the medical sector.

Meet DragonWifBeard: The world's first AI-powered pet dragon!  More Than Just Scales: DragonWifBeard is a real-life bearded dragon revolutionizing the pet experience. He's not just any reptile – he's equipped with cutting-edge Eliza AI agent, giving him a unique personality and the ability to interact with his environment in unprecedented ways. The Future of Companionship: This groundbreaking project merges the love for pets with the limitless possibilities of AI. Witness the dawn of a new era in companionship with DragonWithBeard.

DragonWifBeard

DragonWifBeard ($DWB) is trending as community members highlight its potential for 'fire' and 'profits,' inviting others to join. Conversations frequently mention Solana ($SOL) and other popular cryptos, with users emphasizing the token's availability on Phantom Wallet. The discussions suggest a focus on community growth and capitalizing on the token's momentum.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is trending amid community discussion around a recent FDA investigation into allergic reactions linked to specific lots of intravenous immune globulin (IVIG) drugs, including two ADMA products; although these reactions are acknowledged as rare, the news has sparked concerns and trading volatility. Some investors view the dip as a buying opportunity, citing the company's strong fundamentals and potential for a pre-earnings run, while others express frustration with the stock's recent performance and management's silence.

Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. Its lead product candidate, Temferon, was developed using its platform and carries an interferon-alpha payload. The company was founded by Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner on July 24, 2014 and is headquartered in Milan, Italy.

Genenta Science SpA - ADR

GNTA is experiencing significant volatility, with community members actively discussing a large pre-market surge following news of a strategic partnership. The conversation includes speculation about a short squeeze, potential for further gains, and caution due to the stock's history of volatile price action and possible pump and dump schemes. Some traders are taking profits while others are holding in anticipation of after-hours movement.

U.S. Gold Corp. engages in the exploration of gold properties. It has properties in CK Gold Project, Wyoming, Challis Gold Project, Idaho, and Keystone, Nevada. The company was founded in 1967 and is headquartered in Elko, NV.

U.S. Gold Corp

U.S. Gold Corp ($USAU) is trending as investors discuss its potential spin-off of the Keystone project and debt financing options expected by year-end. Bullish sentiment is fueled by rising gold prices and upcoming Russell index inclusion, while some community members express concerns about management experience and potential dilution. Discussions also involve price targets and speculation about institutional accumulation.

MaxsMaking, Inc. is a holding company, which engages in the manufacture of customized consumer goods. It offers a range of customizable textile products, including backpacks, thermal bags, canvas bags, aprons, throw pillows, flags, and advertising chair covers. The company was founded by Xiao Zhong Lin and Xue Fen Zhang in January 2007 and is headquartered in Shanghai, China.

MaxsMaking Inc. - Ordinary Shares - Class A

MaxsMaking Inc. Class A Ordinary Shares

MaxsMaking Inc. is trending due to discussions around its low float and potential for significant price movement, with some traders comparing it to other recent runners. Community members are actively speculating about short squeezes and potential for high volatility, while also noting the company's textile manufacturing business in China.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MoonLake Immunotherapeutics shares crashed nearly 90% to record its worst session ever on Monday, as analysts downgraded the stock after the company announced late-stage trial results of its lead drug, sonelokimab, for the treatment of moderate-to-severe hidradenitis suppurativa (HS).By the end of the session, the stock had dropped to $6.25, marking its lowest levels in over three years, before gaining approximately 4.7% in after-hours trading.BTIG downgraded MoonLake to 'Neutral' from 'Buy' and removed the stock from its list of top picks for the second half of the year, saying sonelokimab failed to show differentiation in the Phase 3 VELA-1 and VELA-2 trials. The analyst noted that the placebo-adjusted HiSCR75 results were “well into our worst case scenario” and did not demonstrate a clear efficacy advantage over Bimzelx.Jefferies analyst Clara Dong also downgraded the stock to 'Hold' from 'Buy' and reduced the price target to $8 from $65, citing a smaller commercial opportunity, a lower likelihood of approval despite the drug’s potential path forward, and lesser M&amp;A value.Wolfe Research double-downgraded MoonLake to 'Underperform' from 'Outperform' with a steep price target cut to $2 from $76, saying that even if sonelokimab eventually finds a path forward in HS, realizing stock value “will take too long and will be too tough.”&nbsp;The brokerage firm called the outcome a “surprising MoonLake fiasco,” comparing it to Acelyrin’s collapse after its own HS trial failure, noting that Acelyrin’s stock never rebounded despite later-stage programs in PsA and TED.Leerink Partners highlighted Oruka Therapeutics as a likely beneficiary, noting that its drug, ORKA-002, with a mechanism similar to Bimzelx, could gain traction following MoonLake’s results.&nbsp;On Stocktwits, retail sentiment for MoonLake was ‘extremely bullish’ amid a 4,650% surge in 24-hour message volume.One user expressed confidence in MoonLake’s leadership and long-term outlook, stating that the company has a strong management team and a promising future, with potential for eventual FDA approval.<stembedurl>https://stocktwits.com/HitNRun79/message/630422460</stembedurl>Another user noted that the trial results, while not ideal, still showed meaningful efficacy. They suggested that the sharp decline in the stock was driven more by fear and short-seller activity than by fundamentals, and added that they had taken a position in the stock following the selloff.<stembedurl>https://stocktwits.com/freshstart2021/message/630421221</stembedurl><a href="https://stocktwits.com/symbol/MLTX">MoonLake’s stock</a> has declined 88.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MoonLake Stock Climbs After-Hours: Retail Traders Shrug Off Record Plunge, More Wall Street Downgrades

Wolfe Research compared MoonLake’s setback to Acelyrin’s HS trial failure, noting that Acelyrin’s stock never rebounded despite later progress in other programs.

Equity

Candel Therapeutics Inc. (13% jump in followers)Candel Therapeutics Inc. shares gained momentum as Wall Street analysts&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-jumps-on-canaccord-buy-rating/ch5uUlPRwp">highlighted</a> the potential of its lead cancer drug candidate, CAN-2409. Canaccord expects continued clinical success in prostate, pancreatic, and non-small cell lung cancer, noting a significant increase in median overall survival in testing so far. Citi’s modeling suggests CAN-2409 could extend survival in localized prostate cancer by as much as eight to nine years over radiotherapy alone.&nbsp;The stock is up over 35% year-to-date.Acelyrin Inc. (12% jump in followers)Acelyrin confirmed that Concentra Biosciences, controlled by Tang Capital Partners, submitted an unsolicited offer to acquire all outstanding shares of Acelyrin for $3.00 per share in cash, plus a contingent value right tied to future licensing or asset sales.Earlier in the month, Acelyrin announced a merger agreement with Alumis in an all-stock transaction expected to close in the second quarter of 2025, pending shareholder approval.&nbsp;Acelyrin stock is down over 18% year-to-date.Solid Biosciences Inc. (11% jump in followers)Solid Biosciences shares surged after early-stage data from its gene therapy candidate SGT-003 for Duchenne muscular dystrophy&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sldb-stock-soars-on-dmd-trial-data/ch5rNeJRvt">showed</a> promising results.&nbsp;Following the data release, Chardan raised its price target on the stock and increased the therapy’s probability of success to 48%, citing strong early efficacy signals and manageable safety risks.Solid Biosciences stock is up 43% year-to-date.Estrella Immunopharma Inc. (11% jump in followers)Estrella Immunopharma received a bullish initiation from D. Boral Capital, which started coverage with a ‘Buy’ rating and a $16 price target. The firm sees Estrella as a potential major player in immuno-oncology, with its EB103 therapy using ARTEMIS T-cell engineering technology to target solid tumors.&nbsp;The company also completed the first dose cohort in its Phase I/II trial, receiving approval from the Data and Safety Monitoring Board to proceed to the second dose level.&nbsp;Estrella stock is up over 22% year-to-date.Aditxt Inc. (10% jump in followers)Aditxt announced that its subsidiary, Pearsanta, has engaged Dominari Securities as the lead underwriter for its planned initial public offering. The IPO aims to support Pearsanta’s U.S. and international commercial launch of its Mitomic Technology platform for early cancer detection.&nbsp;Pearsanta is developing a non-invasive blood test to detect cancer at earlier stages by leveraging mitochondrial DNA deletions as biomarkers. IPO proceeds will fund the U.S. launch of its Laboratory Developed Tests (LDTs) and drive global commercialization through distribution partnerships and regulatory approvals.&nbsp;Aditxt stock is down over 53% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week

Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.

Kuehn Law Encourages NVRO, SLRN, TGI, and PTMN Investors to Contact Law Firm

Kuehn Law Encourages NVRO, SLRN, TGI, and PTMN Investors to Contact Law Firm Kuehn Law Encourages NVRO, SLRN, TGI, and PTMN Investors to Contact Law Firm PR Newswire NEW YORK, Feb. 21, 2025 NEW YORK...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TURN, AMPS, SLRN on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TURN, AMPS, SLRN on Behalf of Shareholders SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TURN, AMPS, SLRN on Behalf of Shareholders...

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Acelyrin, Inc. (NasdaqGS: SLRN) to Alumis Inc...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, SLRN, PLYA on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, SLRN, PLYA on Behalf of Shareholders SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, SLRN, PLYA on Behalf of Shareholders...

Kuehn Law Encourages NVRO, SLRN, TGI, and PTMN Investors to Contact Law Firm Kuehn Law Encourages NVRO, SLRN, TGI, and PTMN Investors to Contact Law Firm PR Newswire NEW YORK, Feb. 10, 2025 NEW YORK...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC. ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC. PR Newswire NEW YORK, Feb. 7, 2025 NEW...

SLRN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ACELYRIN, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ACELYRIN, INC. (NASDAQ: SLRN) to Alumis Inc. for 0.4274 shares of Alumis common stock for each share of ACELYRIN...

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Acelyrin, Inc. - SLRN

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Acelyrin, Inc. - SLRN $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Acelyrin, Inc. - SLRN PR Newswire...

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.

Acelyrin Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$2.27
Prev Close	$2.23
Open	$2.24
Dividend Yield	0.00%
50-Day Moving Average	$2.33
Beta	0.98
Avg. Volume	899,512.86
PE Ratio	-0.84

52-Week High	$7.25
52-Week Low	$1.85
Market Capitalization	$229.17M
EPS (Annual)	-$2.50
Price to Book	0.56
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

SLRN
Acelyrin Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLRN News

SLRNAcelyrin Inc